Unity Biotechnology (NASDAQ:UBX) Announces Quarterly Earnings Results

Unity Biotechnology (NASDAQ:UBX) announced its quarterly earnings data on Tuesday. The company reported ($0.43) earnings per share for the quarter, meeting the consensus estimate of ($0.43), Zacks reports.

Unity Biotechnology Stock Performance

Shares of UBX opened at $0.99 on Thursday. The firm has a market capitalization of $16.63 million, a P/E ratio of -0.75 and a beta of 1.30. Unity Biotechnology has a 52 week low of $0.85 and a 52 week high of $3.10. The stock has a 50 day moving average price of $1.40 and a two-hundred day moving average price of $1.44.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on UBX shares. Chardan Capital reaffirmed a “buy” rating and set a $4.00 price target on shares of Unity Biotechnology in a research note on Wednesday. HC Wainwright reissued a “buy” rating and issued a $4.00 price target on shares of Unity Biotechnology in a research report on Wednesday.

Unity Biotechnology Company Profile

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.